Physician profile
Christopher O Ike
NPI 1043346893
$7,103.85
in general payments reported to CMS, 2019-2025
21 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,554 · 2020: $287 · 2021: $367 · 2022: $423 · 2023: $473 · 2024: $467 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900 · Travel and Lodging: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,900.00 |
| Travel and Lodging | $573.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,680.41 | 2019-2025 | General - Vascular Access |
| Cardiovascular Systems INC. | $1,144.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $719.73 | 2019-2025 | |
| Pfizer INC. | $690.36 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $660.15 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $399.37 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $224.62 | 2019-2024 | Cardiomems, Confirm Rx, Assurity |
| Philips North America LLC | $111.53 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Medtronic, INC. | $90.13 | 2022-2024 | Avalus, Onyx Frontier |
| Amgen INC. | $60.28 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $54.79 | 2019-2025 | Farxiga |
| Celonova Biosciences, INC. | $52.22 | 2019-2020 | |
| Irhythm Technologies, INC. | $43.11 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $41.12 | 2019-2020 | |
| Medtronic Vascular, INC. | $32.92 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $22.30 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2021 | |
| Asahi Intecc USA, INC. | $16.30 | 2025 | Asahi Coronary Wires |
| Kiniksa Pharmaceuticals International, Plc | $14.16 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.